Efficacy and biomarker findings from AVaglio, a phase III trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma von Cloughesy, T, Mason, W, Henriksson, R, Saran, F, Nishikawa, R, Hilton, M, Garcia, J, Pallaud, C, Chinot, O

Volltext

9003 ORAL Biomarker Analysis in BO21015, a Phase II Randomised Study of First-line Bevacizumab (BEV) Combined With Carboplatin-gemcitabine (CG) or Carboplatin-paclitaxel (CP) in Pa... von Mok, T, Gorbunova, V, Juhasz, E, Szima, B, Burdaeva, O, Yu, C.J, Delmar, P, Pallaud, C, Jonnaert, M, Reck, M

Volltext

Genetic influences on lipid metabolism trait variability within the Stanislas Cohort von Pallaud, C., Gueguen, R., Sass, C., Grow, M., Cheng, S., Siest, G., Visvikis, S.

Volltext

APOC3, CETP, fibrinogen, and MTHFR are genetic determinants of carotid intima-media thickness in healthy men (the Stanislas Cohort) von Pallaud, C, Sass, C, Zannad, F, Siest, G, Visvikis, S

Volltext

Immune profiles in acute myeloid leukemia bone marrow associate with patient age, T-cell receptor clonality, and survival von Brück, Oscar, Dufva, Olli, Hohtari, Helena, Blom, Sami, Turkki, Riku, Ilander, Mette, Kovanen, Panu, Pallaud, Celine, Ramos, Pedro Marques, Lähteenmäki, Hanna, Välimäki, Katja, El Missiry, Mohamed, Ribeiro, Antonio, Kallioniemi, Olli, Porkka, Kimmo, Pellinen, Teijo, Mustjoki, Satu

Volltext

Candidate gene polymorphisms in cardiovascular disease : A comparative study of frequencies between a French and an Italian population von PALLAUD, Céline, STRANIERI, Chiara, SASS, Catherine, SIEST, Gérard, PIGNATTI, Franco, VISVIKIS, Sophie

Volltext

Clinical Genotyping and Efficacy Outcomes: Exploratory Biomarker Data from the Phase II Abigail Study of 1st-Line Bevacizumab + Chemotherapy in Non-Squamous Non-Small-Cell Lung Can... von Pallaud, C., Reck, M., Juhasz, E., Szima, B., Yu, C., Burdaeva, O., Orlov, S., Scherer, S.J., Archer, V., Mok, T.S.K.

Volltext

Tumour Biomarker and Plasma Time Course Data from Abigail, A Phase II Study of 1st-Line Bevacizumab + Chemotherapy in Advanced Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC) von Reck, M., Gorbunova, V.A., Juhasz, E., Szima, B., Orlov, S., Yu, C., Pallaud, C., Scherer, S.J., Archer, V., Mok, T.S.K.

Volltext

Biomarker (BM) Results from the Phase III Averel Trial of 1st-Line Bevacizumab (BV), Trastuzumab (H) + Docetaxel (T) for HER2-Positive Locally Recurrent/Metastatic Breast Cancer (L... von Gianni, L., Chan, A., Mansutti, M., Pivot, X., Greil, R., Provencher, L., Prot, S., Moore, N., Scherer, S.J., Pallaud, C.

Volltext

1657P - Biomarker (BM) Results from the Phase III Averel Trial of 1st-Line Bevacizumab (BV), Trastuzumab (H) + Docetaxel (T) for HER2-Positive Locally Recurrent/Metastatic Breast C... von Gianni, L., Chan, A., Mansutti, M., Pivot, X., Greil, R., Provencher, L., Prot, S., Moore, N., Scherer, S.J., Pallaud, C.

Volltext

A multilocus genotyping assay for candidate markers of cardiovascular disease risk von Cheng, S, Grow, M A, Pallaud, C, Klitz, W, Erlich, H A, Visvikis, S, Chen, J J, Pullinger, C R, Malloy, M J, Siest, G, Kane, J P

Volltext

Abstract P3-06-34: Plasma (p) VEGF-A and VEGFR-2 biomarker (BM) results from the BEATRICE phase III trial of bevacizumab (BEV) in triple-negative early breast cancer (BC) von Carmeliet, P, Pallaud, C, Deurloo, RJ, Bubuteishvili-Pacaud, L, Henschel, V, Dent, R, Bell, R, Mackey, J, Scherer, SJ, Cameron, D

Volltext

Biomarker (BM) Results from GOG-0218, a Phase 3 Trial of Front-Line Bevacizumab (BV) + Chemotherapy (CT) for Ovarian Cancer (OC) von Birrer, M.J., Lankes, H., Burger, R.A., Mannel, R., Homesley, H., Henschel, V., Sovak, M., Scherer, S.J., de Haas, S., Pallaud, C.

Volltext

198P - Biomarker (BM) Results from GOG-0218, a Phase 3 Trial of Front-Line Bevacizumab (BV) + Chemotherapy (CT) for Ovarian Cancer (OC) von Birrer, M.J., Lankes, H., Burger, R.A., Mannel, R., Homesley, H., Henschel, V., Sovak, M., Scherer, S.J., de Haas, S., Pallaud, C.

Volltext

Familial Studies on the Genetics of Cardiovascular Diseases: the Stanislas Cohort von Visvikis, Sophie, Sass, Catherine, Pallaud, Celine, Grow, Michael A., Zannad, Faiez, Siest, Gérard, Erlich, Henry A., Cheng, Suzanne

Volltext

PS968 GENETIC LANDSCAPE OF FLT3‐MUTATED ACUTE MYELOID LEUKEMIA (AML) PATIENTS TREATED WITHIN THE RATIFY TRIAL: CALGB 10603 (ALLIANCE) von Jahn, N., Panina, E., Bullinger, L., Dolnik, A., Herzig, J., Blätte, T.J., Benner, A., Gambietz, A., Krzykalla, J., Gathmann, I., Larson, R.A., Lo‐Coco, F., Amadori, S., Prior, T.W., Brandwein, J.M., Appelbaum, F.R., Medeiros, B.C., Tallman, M.S., Tiecke, E., Pallaud, C., Ehninger, G., Heuser, M., Ganser, A., Stone, R.M., Thiede, C., Döhner, H., Bloomfield, C.D., Döhner, K.

Volltext

Sample size calculations for classical association and TDT-type methods using family data von TREGOUET, D. A., PALLAUD, C., SASS, C., VISVIKIS, S., TIRET, L.

Volltext

Sample size calculations for classical association and TDT‐type methods using family data von TREGOUET, D. A., PALLAUD, C., SASS, C., VISVIKIS, S., TIRET, L.

Volltext

PF260 PROGNOSTIC AND PREDICTIVE IMPACT OF NPM1/FLT3‐ITD GENOTYPES AS DEFINED BY 2017 EUROPEAN LEUKEMIANET RISK CATEGORIZATION FROM AML PATIENTS TREATED WITHIN THE INTERNATIONAL RAT... von Döhner, K., Thiede, C., Jahn, N., Ekaterina, P., Gambietz, A., Prior, T.W., Marcucci, G., Jones, D., Krauter, J., Michael, H., Lo‐Coco, F., Ottone, T., Nomdedeu, J., Mandrekar, S.J., Huebner, L., Laumann, K.M., Geyer, S.M., Klisovic, R.B., Wei, A., Sierra, J., Sanz, M.A., Brandwein, J.M., Witte, T.M., Jansen, J.H., Niederwieser, D., Appelbaum, F.R., Medeiros, B.C., Tallman, M.S., Schlenk, R.F., Ganser, A., Serve, H., Ehninger, G., Amadori, S., Gathmann, I., Axel, B., Pallaud, C., Larson, R.A., Stone, R.M., Döhner, H., Bloomfield, C.D.

Volltext

Multilocus approach to cardiovascular risk von Pallaud, C., Maurice, M., Cheng, S., Grow, M., Aguillon, D., Sass, C., Siest, G., Visvikis, S.

Volltext